With preclinical data suggesting rapid tumour blood vessel regrowth following cessation of VEGF inhibition (Mancuso et al, 2006), one may advocate the continuation of bevacizumab alone until disease progression in the event of cytotoxic drug-induced adverse events. The gene discussed is VEGFA; the disease is neoplasm.